Although trogocytosis has been recognized as a means of acquired resistance to CAR T-cell therapies (Hamieh et al, 2019) via reversible antigen loss on tumor cells, we did not observe a decrease in target antigen density on MOLM13-TP53-/- AML cells (Fig. EV1I; Appendix Fig. S4A). The gene discussed is TP53; the disease is neoplasm.